Cardiol Therapeutics wins US patent protection for heart-disease drug platform
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Subscribe To Our Newsletter & Stay Updated